Loading...
XNAS
GLPG
Market cap1.92bUSD
May 28, Last price  
29.13USD
1D
0.55%
1Q
10.63%
Jan 2017
-54.62%
IPO
145.82%
Name

Galapagos NV

Chart & Performance

D1W1MN
P/E
22.94
P/S
6.17
EPS
1.12
Div Yield, %
—
Shrs. gr., 5y
2.74%
Rev. gr., 5y
-20.07%
Revenues
276m
+14.99%
11,240,00035,152,00065,936,00076,978,00093,089,000122,410,00095,887,000136,268,000137,699,00069,368,00039,563,000129,517,000127,087,000288,836,000844,986,000478,053,000484,846,000505,280,000239,724,000275,649,000
Net income
74m
-65.01%
-6,541,000-11,335,000-21,948,000-14,584,0003,010,0004,370,000-33,097,000-5,721,000-8,079,00033,211,000-118,410,00054,012,000-115,704,000-29,259,000149,845,000-311,001,000-125,422,000-217,991,000211,697,00074,082,000
CFO
-320m
L-21.17%
-3,887,000-9,310,000371,000-8,209,0006,303,000-18,573,000-11,991,00064,104,000522,000-75,555,000-114,590,000239,403,000-147,030,000-142,466,0003,208,617,000-427,336,000-503,827,000-500,544,000-405,970,000-320,026,000

Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
URL
https://www.glpg.com/
IPO date
May 06, 2005
Employees
1,233
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
275,649
14.99%
239,724
-52.56%
505,280
4.21%
Cost of revenue
467,202
371,535
766,690
Unusual Expense (Income)
NOPBT
(191,553)
(131,811)
(261,410)
NOPBT Margin
Operating Taxes
(1,803)
9,613
2,844
Tax Rate
NOPAT
(189,750)
(141,424)
(264,254)
Net income
74,082
-65.01%
211,697
-197.11%
(217,991)
73.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,770
6,695
BB yield
-0.07%
-0.25%
Debt
Debt current
3,479
4,652
7,209
Long-term debt
19,965
14,540
36,593
Deferred revenue
838,876
1,623,599
Other long-term liabilities
35,920
1,105,056
27,348
Net debt
(3,347,252)
(3,678,884)
(4,174,770)
Cash flow
Cash from operating activities
(320,026)
(405,970)
(500,544)
CAPEX
(16,720)
(18,706)
(36,947)
Cash from investing activities
220,597
71,186
(1,245,514)
Cash from financing activities
(4,924)
(5,001)
(1,487)
FCF
(186,327)
(113,492)
(280,994)
Balance
Cash
3,117,573
3,684,501
4,094,062
Long term investments
253,123
13,575
124,510
Excess cash
3,356,914
3,686,090
4,193,308
Stockholders' equity
159,945
58,572
(209,531)
Invested Capital
3,623,512
3,851,646
4,407,383
ROIC
ROCE
EV
Common stock shares outstanding
65,942
65,933
65,699
Price
26.52
-28.30%
36.99
-10.54%
41.35
-15.99%
Market cap
1,748,782
-28.30%
2,438,862
-10.23%
2,716,654
-15.73%
EV
(1,598,470)
(1,240,022)
(1,458,116)
EBITDA
(146,054)
(88,169)
(195,844)
EV/EBITDA
10.94
14.06
7.45
Interest
315
1,654
6,967
Interest/NOPBT